- Stocks
- Pharma & Healthcare
- Sanofi India
Sanofi India share price
NSE: SANOFIPharma & HealthcareDrug Manufacturers - General
Sanofi India at a glance
Sanofi India (NSE: SANOFI) closed at ₹2,845.00 on 22 Oct 2026, up 0.53% on the day. With a market capitalisation of ₹6,552 Cr, it ranks 688th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 21.2× trailing earnings, against a return on equity of 48.0% in FY25. Over the past year the share price has fallen 40.0%. Its 52-week range is ₹2,796.00 (22 Oct 2026) to ₹4,898.00 (29 Oct 2025); the last close is 41.9% below the high. In Q3 FY25, the quarter ended 31 Dec 2024, revenue was ₹515 Cr (−25.8% year on year) and net profit ₹91 Cr (−33.7%), on a consolidated basis. Promoters held 60.40% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹6,552 CrRank 688 on NSE
- P/E (trailing)
- 21.2×
- Price to book
- 16.36×FY25
- EPS (TTM)
- ₹179.45to Q3 FY25
- ROE
- 48.0%FY25
- ROCE
- 52.7%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 20.5%FY25
- Book value / share
- ₹374.17FY25
- 52-week high
- ₹4,898.0029 Oct 2025
- 52-week low
- ₹2,796.0022 Oct 2026
- 1-year return
- −40.0%
- RSI (14-day)
- 27.7
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.53% | −4.6% | −7.6% | −16.5% | −40.0% |
Sanofi India quarterly results
| Quarter | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹737 Cr | ₹706 Cr | ₹715 Cr | ₹694 Cr | ₹732 Cr | ₹464 Cr | ₹524 Cr | ₹515 Cr |
| Revenue YoY | — | — | — | — | −0.6% | −34.4% | −26.7% | −25.8% |
| Net profit | ₹190 Cr | ₹123 Cr | ₹152 Cr | ₹138 Cr | ₹137 Cr | ₹103 Cr | ₹82 Cr | ₹91 Cr |
| Net profit YoY | — | — | — | — | −28.3% | −16.0% | −45.9% | −33.7% |
| Net margin | 25.9% | 17.4% | 21.3% | 19.8% | 18.7% | 22.3% | 15.7% | 17.7% |
| EPS | ₹82.78 | ₹53.37 | ₹65.95 | ₹59.79 | ₹59.31 | ₹44.81 | ₹35.69 | ₹39.64 |
Sanofi India financials
| Item | FY24 | FY25 |
|---|---|---|
| Revenue | ₹2,851 Cr | ₹2,013 Cr |
| Operating profit | ₹828 Cr | ₹469 Cr |
| Net profit | ₹603 Cr | ₹413 Cr |
| EPS (₹) | ₹262.00 | ₹179.00 |
| Cash from operations | ₹230 Cr | ₹462 Cr |
| Total debt | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹1,015 Cr | ₹861 Cr |
Sanofi India shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% |
| Foreign institutions | 5.57% | 5.61% | 5.57% | 5.55% | 5.64% | 5.69% |
| Domestic institutions | 23.02% | 23.06% | 22.29% | 21.31% | 21.13% | 19.87% |
| Non-institutions | 11.01% | 10.94% | 11.75% | 12.74% | 12.83% | 14.04% |
Sanofi India vs peers
The listed Pharma & Healthcare companies nearest to Sanofi India by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MOREPENLABMorepen Laboratories | ₹125.70 | +5.63% | +141.6% | ₹6,888 Cr | 72.7 | — |
| SUPRIYASupriya Lifescience | ₹848.80 | −0.02% | +19.4% | ₹6,831 Cr | 32.7 | — |
| BLISSGVSBliss GVS Pharma | ₹638.00 | +2.42% | +319.4% | ₹6,766 Cr | 53.1 | — |
| SANOFISanofi India | ₹2,845.00 | +0.53% | −40.0% | ₹6,552 Cr | 21.2 | — |
| ENTEROEntero Healthcare Solutions | ₹1,504.20 | −0.19% | +36.0% | ₹6,547 Cr | 57.1 | — |
| KOVAIKovai Medical Center & Hospital | ₹5,738.00 | −2.24% | +190.4% | ₹6,279 Cr | 25.7 | — |
| NEPHROPLUSNephrocare Health Services | ₹599.90 | −0.84% | — | ₹6,019 Cr | 74.1 | — |
Ask anything about Sanofi India
Pivot answers on the live chart with evidence you can check, and tests strategies against SANOFI's own history. Try: “Why has SANOFI moved over the last three months?” · “Backtest a 50-day moving-average crossover on SANOFI over five years” · “Compare SANOFI with MOREPENLAB on margins and valuation”
Frequently asked questions about Sanofi India
What is the share price of Sanofi India today?
Sanofi India (NSE: SANOFI) last closed at ₹2,845.00 on 22 Oct 2026. Its 52-week high is ₹4,898.00 and its 52-week low is ₹2,796.00.
What is the market cap of Sanofi India?
Sanofi India's market capitalisation is ₹6,552 Cr (₹6,552 Cr) at the 22 Oct 2026 close, ranking 688th among the NSE companies Pivot tracks.
What is the P/E ratio of Sanofi India?
Sanofi India trades at a trailing P/E of 21.2. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 57.1.
What is the ROE and ROCE of Sanofi India?
Return on equity was 48.0% in FY25 and return on capital employed was 52.7% in FY25 (consolidated figures).
Is Sanofi India a debt-free company?
Sanofi India is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Sanofi India's latest quarterly results?
For Q3 FY25 (quarter ended 31 Dec 2024), Sanofi India reported revenue of ₹515 Cr, −25.8% year on year, and net profit of ₹91 Cr, −33.7% year on year.
How has Sanofi India stock performed over the last year?
Sanofi India's share price has fallen 40.0% over the past year, −16.5% over three months and −7.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Sanofi India?
As of 30 Jun 2026: promoters 60.40%, foreign institutions 5.69%, domestic institutions 19.87%, non-institutions 14.04%.
Who are Sanofi India's competitors?
The listed Pharma & Healthcare companies closest to Sanofi India by market cap are Morepen Laboratories, Supriya Lifescience, Bliss GVS Pharma, Entero Healthcare Solutions, Kovai Medical Center & Hospital and Nephrocare Health Services.
Is Sanofi India a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Sanofi India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SANOFI against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text